We’re making changes to our membership offerings, tools, and features. Learn More

IN BRIEF: Eden Research signs thymol supply deal with Veto-pharma

Eden Research PLC - Oxfordshire, England-based developer of biopesticides and formulation ...

Alliance News 11 April, 2025 | 1:17PM
Email Form Facebook Twitter LinkedIn RSS

Eden Research PLC - Oxfordshire, England-based developer of biopesticides and formulation technologies for the crop protection, animal health and consumer products industries - Announces that it has signed an agreement with Veto-pharma to supply thymol for use in bee care products. Veto-pharma is a Palaiseau, France-based animal health pharmaceutical laboratory with a dedicated research centre focused on bee health, and intends to use the thymol in its varroa mite treatment for bee hives. Eden notes that thymol is one of the three active ingredients in Eden's suite of biopesticide products and is currently registered in the EU and the US.

Chief Executive Officer Sean Smith comments: "We are always looking for opportunities to leverage our existing registrations and technologies to diversify our product portfolio and revenue streams. This represents a meaningful contribution to that strategy, while also enhancing the return on investments made in active ingredient dossiers across the EU, the US, and other markets. We are pleased to be working with our new partner, Veto-pharma and supporting them in making their product a great success. We anticipate there will be additional opportunities in the future to further expand this relationship."

Current stock price: 2.75 pence, down 5.3% on Friday afternoon in London

12-month change: down 46%

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Eden Research PLC 2.55 GBX 0.00 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures